PremiumCompany AnnouncementsEntrada Therapeutics Reports Strong 2024 Financial Results Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year PremiumThe FlyEntrada announces FDA removal of clinical hold on ENTR-601-44 Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial PremiumThe FlyEntrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright Entrada Therapeutics’ Q3 2024 Financial Highlights Entrada Therapeutics reports Q3 EPS (35c), consensus (73c) 
